Joint supplements are commonly given to dogs with arthritis and degenerative joint disease, with varying levels of evidence supporting different products and welfare impacts.
The welfare implications of joint supplement use in dogs involve both the potential benefit of pain reduction and the risk that supplements providing inadequate analgesia may delay use of more effective treatments like NSAIDs. Dogs suffering from arthritic pain whose owners rely primarily on supplements of uncertain efficacy may endure unnecessary chronic pain while appearing to receive treatment. However, omega-3 fatty acids and some other supplements have genuine anti-inflammatory effects that contribute meaningfully to pain management when used as part of a multi-modal approach. The key welfare consideration is ensuring that supplement use is part of a comprehensive pain management strategy rather than a substitute for veterinary assessment and appropriate pharmaceutical intervention when needed.